Drug Profile
CNTO 3157
Alternative Names: CNTO-3157; JNJ-42915925; PRV-300Latest Information Update: 02 May 2023
Price :
$50
*
At a glance
- Originator Centocor Ortho Biotech; MorphoSys
- Developer Janssen Biotech; Provention Bio
- Class Anti-inflammatories; Antiasthmatics; Bronchodilators; Monoclonal antibodies
- Mechanism of Action Toll-like receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
- No development reported Ulcerative colitis
Most Recent Events
- 27 Apr 2023 Provention Bio has been acquired by Sanofi
- 28 Feb 2021 No recent reports of development identified for phase-I development in Ulcerative-colitis in Georgia (IV, Infusion)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Ulcerative-colitis in Moldova (IV, Infusion)